19619-22-8

Basic information

• Product Name: 2,4-dicyanoaniline
• Synonyms: 2,4-dicyanoaniline;4-Amino-1,3-benzenedicarbonitrile;4-Aminoisophthalonitrile;Einecs 243-188-1
• CAS NO: 19619-22-8
• Molecular Formula: C₈H₅N₃
• Molecular Weight: 143.1454
• EINECS: 243-188-1
• Mol File: 19619-22-8.mol
• Article Data: 11

Chemical Properties

• Melting Point: 217-218 °C
• Boiling Point: 332.1°C at 760 mmHg
• Flash Point: 154.7°C
• Appearance: /
• Density: 1.26g/cm³
• Vapor Pressure: 0.000149mmHg at 25°C
• Refractive Index: 1.612
• PKA: -1.06±0.10(Predicted)
• CAS DataBase Reference: 2,4-dicyanoaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-dicyanoaniline(19619-22-8)
• EPA Substance Registry System: 2,4-dicyanoaniline(19619-22-8)

Safety Data

• Hazardous Substances Data: 19619-22-8(Hazardous Substances Data)

Usage

General Description

2,4-dicyanoaniline is a chemical compound with the formula C8H6N4. It is a yellow crystalline solid that is used in the production of dyes and pigments, as well as in the synthesis of pharmaceuticals. It is a strong electron-withdrawing compound due to its cyano groups, which makes it useful in organic chemistry reactions. 2,4-dicyanoaniline can also be used as a corrosion inhibitor in industrial processes, as well as a building block for the production of materials such as plastics, resins, and adhesives. It is important to handle this chemical with care as it can be toxic and irritating to the skin, eyes, and respiratory system.

InChI:InChI=1/C8H5N3/c9-4-6-1-2-8(11)7(3-6)5-10/h1-3H,11H2

Upstream product

• 33348-34-4 4-amino-3-iodobenzonitrile 
• 557-21-1 zinc(II) cyanide 
• 39263-32-6 2-amino-5-bromobenzonitrile 
• 65426-59-7 4-nitrobenzene-1,3-dicarboxylic acid diamide 
• 88678-15-3 4-nitroisophthalic acid dichloride 
• 4315-09-7 4-nitroisophthalic acid 
• 615-57-6 2,4-dibromo-aniline 
• 151-50-8 potassium cyanide 
• 619-72-7 4-nitrobenzonitrile 
• 52054-41-8 4-nitroisophthalonitrile 
• 544-92-3 copper(I) cyanide 

Downstream Products

• 97510-14-0 4-(4-Cyano-phenylamino)-isophthalonitrile 
• 1269142-40-6 C₁₈H₂₉N₃O₄ 
• 1269142-44-0 C₂₈H₃₆N₄O₆ 
• 1269142-46-2 C₃₃H₄₄N₄O₇ 
• 1269400-62-5 C₁₈H₂₀N₄O₂ 
• 1334331-27-9 2,4-dioxo-1,2,3,4-tetrahydroquinazoline-7-carbonitrile 
• 1075253-54-1 C₂₈H₃₁N₇OSSi 
• 74192-47-5 4-amino-3-cyanobenzoic acid 
• 99767-45-0 2-amino-5-cyanobenzoic acid 
• 159847-81-1 methyl 2-AMINO-5-CYANOBENZOATE 
• 159847-80-0 4-amino-3-cyanobenzoic acid methyl ester 

Relevant articles and documents

Palladium/N-Heterocyclic carbene catalyzed mono- and double-cyanation of aryl halides using potassium ferrocyanide trihydrate under aerobic conditions

Abstract A practical palladium/N-heterocyclic carbene catalyzed procedure for the mono- and double-cyanation of aryl halides is described using inexpensive, easy-to-handle and nontoxic potassium ferrocyanide trihydrate {K4[Fe(CN)6]·3H2O} as the cyanating agent. The reaction does not require an anhydrous solvent, or the exclusion of air or moisture. A variety of electron-rich and electron-deficient aryl halides are efficiently converted into their corresponding nitriles and dicarbonitriles.

Design, structure-activity relationships and in vivo characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: Novel class of receptor tyrosine kinase inhibitors

The inhibition of key receptor tyrosine kinases (RTKs) that are implicated in tumor vasculature formation and maintenance, as well as tumor progression and metastasis, has been a major focus in oncology research over the last several years. Many potent small molecule inhibitors of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) kinases have been evaluated. More recently, compounds that act through the complex inhibition of multiple kinase targets have been reported and may exhibit improved clinical efficacy. We report herein a series of potent, orally efficacious 4-amino- 3-benzimidazol-2-ylhydroquinolin-2-one analogues as inhibitors of VEGF, PDGF, and fibroblast growth factor (FGF) receptor tyrosine kinases. Compounds in this class, such as 5 (TKI258), are reversible ATP- competitive inhibitors of VEGFR-2, FGFR-1, and PDGFRβ with IC50 values 0.1 μM. On the basis of its favorable in vitro and in vivo properties, compound 5 was selected for clinical evaluation and is currently in phase I clinical trials.

Combination therapy with CHK1 inhibitors

Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be used in conjunction with DNA damaging agents.